Previous studies in our laboratory have extensively characterized this model for a number of anti-atherogenic interventions relevant to cardiovascular complications of the metabolic syndrome in which RAS activation and AngII elevation play a pathogenic role [38], [44]. This evidence concerns the gene AGT and metabolic syndrome.